APIs lie at the upstream of the pharmaceutical industrial chain, serving as the foundation for guaranteeing drug supply and meeting people's pharmaceutical demand. China is one of the world's major producers and exporters of APIs. Industry experts point out that the implementation of China's volume-based procurement policy will drive the demand for APIs, endowing the industry with high growth potential.
It is known that China officially launched the pilot reform of national centralized drug procurement in 2018, which mainly targeted the generic drug sector. Up to now, the national volume-based procurement of generic drugs has entered the second round. On December 29, 2019, the Joint Procurement Office for National Centralized Drug Procurement and Use issued an announcement. To establish a standardized and regular mechanism for centralized volume-based drug procurement, further reduce the public's medication burden, the second round of national centralized drug procurement and use was launched. At present, the 34 drugs winning the bid in the second round of volume-based procurement are scheduled to be rolled out nationwide this April.
It is noted that with the deepening of volume-based procurement, the survival rule for generic pharmaceutical enterprises has gradually shifted to cost control supremacy. The core logic of volume-based procurement is "trading price for volume": drug prices are lowered by cutting redundant expenses and profits in the drug circulation links; meanwhile, a relatively broad market share and guaranteed clinical application are allocated to qualified drugs with price cuts. The fundamental goal of volume-based procurement is to improve quality and control costs, shifting the generic drug market from marketing-driven to clinical value-driven.

As the upstream link of generic drugs, the API industry is inevitably affected by policy transmission. First, driven by relevant policies, generic pharmaceutical enterprises will refocus their business on the production end. API and intermediate manufacturers with large-scale production capacity will become preferred partners and investment targets for generic drug companies. For instance, Fosun Pharma started investing in building its own API base as early as 2018. On November 27, Shanghai Fosun Pharmaceutical announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical would invest no more than 1 billion yuan in constructing an international API industrial base.
Second, the API industry is expected to expand its market share by leveraging the policy dividends of procurement price cuts, following the path of import substitution previously seen in pharmaceuticals and medical devices. Integrated pharmaceutical enterprises with both preparation and API businesses will gain cost advantages to achieve volume growth through price concessions. This will impact other manufacturers of the same product varieties that cannot deploy high-barrier API businesses in the short term.
In addition, the industry generally believes that the overall status of domestic APIs will be elevated after the implementation of volume-based procurement. Before the policy, chemical preparation manufacturers mostly adopted global procurement for raw materials. After the policy rollout, domestic APIs are expected to achieve substantial import substitution.
Overall, China's API industry features low entry barriers and a large number of small-scale manufacturers, leading to obvious price volatility driven by supply and demand. Nevertheless, supported by export momentum and rigid domestic demand, China's API industry boasts long-term growth drivers. Going forward, combined with the policies of volume-based procurement, generic consistency evaluation, linked review and approval, as well as increasingly stringent environmental regulations, market concentration in bulk and specialty APIs is set to rise. Excess production capacity will be gradually phased out, and the competitive landscape of the API industry will be optimized. Meanwhile, the patent cliff and the window of import substitution will further elevate the overall status of the domestic API industry.












